Find your next quality investment with Simply Wall St’s easy and powerful screener, trusted by over 7 million individual investors worldwide.
-
Pfizer and Valneva reported Phase 3 results for their Lyme disease vaccine candidate, with over 70% efficacy.
-
The trial did not meet its primary endpoint, mainly due to lower than expected Lyme disease incidence during the study.
-
Despite this, the companies view the data as clinically meaningful and plan to move ahead with regulatory submissions.
For investors watching NYSE:PFE, this vaccine update adds a fresh piece to the story around Pfizer beyond its established franchises. The stock trades at $26.77, with a 1 year return of 9.8%, a 3 year return showing a 20.2% decline, and a 5 year return showing a 6.2% decline. In that context, progress in under served areas such as Lyme disease helps illustrate how Pfizer is working to expand its vaccine portfolio.
From here, regulatory review will be important, including how authorities weigh the 70% efficacy figure against the missed primary endpoint. If the vaccine eventually reaches the market, investors may track how it fits into Pfizer’s broader vaccine offerings and what it could mean for the company’s revenue mix, even if initial uptake or labeling is conservative.
Stay updated on the most important news stories for Pfizer by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Pfizer.
We’ve flagged 4 risks for Pfizer. See which could impact your investment.
-
⚖️ Price vs Analyst Target: At US$26.77, Pfizer trades about 6.6% below the US$28.54 analyst target, which is within the typical 10% band.
-
✅ Simply Wall St Valuation: Simply Wall St models Pfizer as trading 56.6% below its estimated fair value.
-
✅ Recent Momentum: The 30 day return of roughly 0.45% shows slightly positive recent momentum.
There is only one way to know the right time to buy, sell or hold Pfizer. Head to Simply Wall St’s company report for the latest analysis of Pfizer’s Fair Value.
-
📊 The Lyme vaccine data underscores Pfizer’s effort to add new vaccines alongside existing products, even when trial statistics are complex.
-
📊 Watch how regulators interpret the 70% efficacy, any labeling constraints, and later, revenue disclosures if the product is approved.
-
⚠️ With four flagged risks including dividend coverage and debt versus cash flow, any extra development or launch costs are worth tracking.
For the full picture including more risks and rewards, check out the complete Pfizer analysis. Alternatively, you can visit the community page for Pfizer to see how other investors believe this latest news will impact the company’s narrative.